Evaluated on growth, margins, recurring-revenue mechanics, capital intensity, and the structural GLP-1 tailwind — with real figures from 2026 reports and competitor price data.
High margin per unit + inherently recurring (consumables, auto-replenish) + low capital to launch (contract manufacturing) + a structural tailwind rivals haven't saturated: the GLP-1 companion & specialty wave (collagen, protein/amino, gut probiotics, personalized nutrition).
Ranked by the blend that defines "lucrative": margin power × growth × recurring/loyalty × low capital × wedge.
| Category | 2026 size | CAGR | Margin power | Recurring / loyalty | Verdict |
|---|---|---|---|---|---|
| 1Wellness / Functional Supplements GLP-1 companion, collagen, protein, gut | ~$230B core | 9–10%+ | High | High · consumable / auto-replen | Most lucrative |
| 2Beauty & Wellness (premium/lux) | $1.87T | 8.9–9.2% | High | Med · brand-led | Strong #2 |
| 3Pet Care (premium) | $190B | 5.9–6.8% | Med-high | High | Good, matured |
| 4Functional Foods | $341B | 9.8% | Med | Med | Dense, regulation |
| 5Broad CPG / FMCG | $12.5T | ~4.6% | Thin | Med | Too broad |
Two chart views: the fast-moving sub-categories inside supplements (the actual money), and how the broad consumer-goods categories stack on growth.
2026 size ($B) — which is actually winnable
Why each lands where it does, with the 2026 numbers behind it. (All figures are estimates from public sources.)
Core supplements ~$230B (2026), growing ~9.5% CAGR to $430–507B by 2034 — roughly twice the rate of conventional food & beverage. Sports-nutrition protein/amino is the largest growth engine at 12.5% CAGR; weight-management 17.9%; probiotics/gut 9.7%; personalized nutrition 13%. North America ~36–37% share, APAC fastest. The structural edge: one-in-eight adults on a GLP-1 drug, spurring the fastest new segment — companion supplements (muscle retention, collagen, gut health, micronutrient). Attractive wedge: consumables, subscribe-and-save/DTC, premium brand + science-backed (health-claim) moat, low capital via contract manufacturing.
$1.87T (2026) growing ~9% toward $2.63T (2030). GLP-1 households spend ~30% more. Strongest premiumisation across wealth tiers; social commerce fastest channel (US ~$100B; TikTok beauty ~$4B 2026, ~260%/yr). Main caveat: requires brand + distribution capital; category is more "revenue/scale" than "moon-margin steam".
$190B (2026) → $284B (2033) ~5.9–6.8% CAGR; strong recurring (subscription replenishment via Chewy etc.). Food = 55%. Loyalty is high but growth is lower and Mars/Purina/Hill's hold steep share; a niche wedge is possible (45% of pet owners) but margin×reach is thinner than supplements.
$341B (2026) at 9.8% CAGR (R&M). Strong tailwind but regulated / dense, lower unit margin, longer time-to-shelf, heavy retailer dependence vs supplements' direct-to-consumer predictability.
$12.5T but only ~4.6% CAGR and thin margins; shelf-space and competition with incumbent MNCs (P&G, Nestlé, Unilever). No wedge for a new entrant.